MicroJect Reactor technology to take centre stage in new partnership

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

leon-nanodrugs and Bionpharma have announced the global cooperation for the development of a dermatological product using leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR).

leon and Bionpharma will co-share the development of this important product. Development will be done at Leon’s US-based formulation partner CoreRx from Clearwater, Florida, a comprehensive CDMO. CoreRx’s facility houses leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR), thereby enabling leon to gain fast access to the key US market. Marketing and distribution of the product will be through Bionpharma in the US and other markets.

It is estimated that over 60% of pharmaceutical APIs are poorly soluble in water. leon’s MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR technology is highly cost effective and easily scalable.

Dr Michael Mehler, CEO of leon-nanodrugs comments: "We are very pleased about the partnership with Bionpharma who share our vision to generate added value to therapeutic molecules through the unique attributes of our MJR Technology. In addition, this co-development is a key strategic step on our way to become a recognized global leader in nanotechnology formulated pharmaceuticals."

Venkat Krishnan, President & CEO of Bionpharma states: "Bionpharma strives to bring uniquely formulated products to the market and this association with leon-nanodrugs is a big step towards this endeavor."